Switching Data, JAK Inhibitor Options, and the Future of Atopic Dermatitis Treatment

In the final episode, 'Switching Data, JAK Inhibitor Options, and the Future of Atopic Dermatitis Treatment,' the expert dermatologist explored the following critical questions:

Besides the head-to-head data, there was also switching data. What did that reveal and why is that important for clinicians?

There are several other Janus kinase (JAK) inhibitors approved for atopic dermatitis (AD). Can you please walk through the other options and how you differentiate between the oral and topical JAK inhibitors in your clinical practice?

What would it take to position an advanced therapy earlier in the treatment algorithm for AD? What kind of evidence is most compelling when you're making formulary decisions?

What emerging data are you most interested in, and how are you thinking about incorporating new evidence into your practice as it becomes available?

Angela Lamb discussed the switching data from the LEVEL UP trial, noting that patients who had not met treatment goals on dupilumab and switched to upadacitinib were able to achieve meaningful improvements, reinforcing the message to patients that failure on one biologic does not preclude success with another. Dr. Lamb then walked through the oral and topical JAK inhibitor landscape, explaining that oral options are reserved for patients with more extensive disease while topical JAK inhibitors serve as valuable adjuncts for breakthrough symptoms in patients already on systemic therapy, with agent selection guided by body surface area involvement, patient age, and concomitant medications. She emphasized that positioning advanced therapies earlier in the treatment algorithm will require compelling real-world evidence demonstrating the full downstream cost savings of optimal disease control, including reductions in depression, anxiety, absenteeism, and healthcare utilization, alongside broader education of dermatologists, pediatricians, and primary care providers about the favorable safety profiles of these agents. Looking ahead, Dr. Lamb expressed particular excitement about OX40 ligand inhibitors and additional JAK inhibitors in the pipeline, and highlighted the importance of staying current through medical meetings and continuing medical education (CME) to ensure patients who are not meeting treatment goals can be offered emerging options as they become available.

Throughout the conversation, the expert provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Insights series on atopic dermatitis (AD). Please subscribe to our newsletter for information on upcoming video series.